

IFW

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM  (to be used for all correspondence after initial filing)	Application Number	10/689,225
	Filing Date	October 20, 2003
	First Named Inventor	GH Cantor
	Art Unit	not yet assigned
	Examiner Name	not yet assigned
Total Number of Pages in This Submission	Attorney Docket Number	01274.US1


ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>Executed Declaration</b> <b>Return Receipt Postcard</b>
Remarks		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Pharmacia & Upjohn Company      Edward F. Rehberg, 34,703	
Signature		
Date	8-03-04	


### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Valerie L. Schipper	
Signature		
	Date	8-03 Aug-2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 0.00)

## Complete if Known

Application Number	10/689,225
Filing Date	October 20, 2003
First Named Inventor	GH Cantor
Examiner Name	not yet assigned
Art Unit	not yet assigned
Attorney Docket No.	01274.US1

## METHOD OF PAYMENT (check all that apply)

 Check  Credit card  Money Order  Other  None
 Deposit Account:

Deposit Account Number	21-0718
Deposit Account Name	Pharmacia & Upjohn Company

The Director is authorized to: (check all that apply)

 Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

## 1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385			Utility filing fee	
1002 340	2002 170			Design filing fee	
1003 530	2003 265			Plant filing fee	
1004 770	2004 385			Reissue filing fee	
1005 160	2005 80			Provisional filing fee	
SUBTOTAL (1)		(\$ 0.00)			

## 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Extra Claims	Fee from below	Fee Paid
Total Claims	-20** = 0	X \$0.00 = \$0.00
Independent Claims	- 3** = 0	X \$0.00 = \$0.00
Multiple Dependent		\$0.00 = \$0.00

Large Entity	Small Entity	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$ 0.00)

\*\* or number previously paid, if greater; For Reissues, see above

## 3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code (\$)	Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65			Surcharge - late filing fee or oath	
1052 50	2052 25			Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130			Non-English specification	
1812 2,520	1812 2,520			For filing a request for ex parte reexamination	
1804 920*	1804 920*			Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*			Requesting publication of SIR after Examiner action	
1251 110	2251 55			Extension for reply within first month	
1252 420	2252 210			Extension for reply within second month	
1253 950	2253 475			Extension for reply within third month	
1254 1,480	2254 740			Extension for reply within fourth month	
1255 2,010	2255 1,005			Extension for reply within fifth month	
1401 330	2401 165			Notice of Appeal	
1402 330	2402 165			Filing a brief in support of an appeal	
1403 290	2403 145			Request for oral hearing	
1451 1,510	1451 1,510			Petition to institute a public use proceeding	
1452 110	2452 55			Petition to revive - unavoidable	
1453 1,330	2453 665			Petition to revive - unintentional	
1501 1,330	2501 665			Utility issue fee (or reissue)	
1502 480	2502 240			Design issue fee	
1503 640	2503 320			Plant issue fee	
1460 130	1460 130			Petitions to the Commissioner	
1807 50	1807 50			Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180			Submission of Information Disclosure Stmt	
8021 40	8021 40			Recording each patent assignment per property (times number of properties)	
1809 770	2809 385			Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385			For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385			Request for Continued Examination (RCE)	
1802 900	1802 900			Request for expedited examination of a design application	

Other fee (specify) \_\_\_\_\_

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0.00)

(Complete if applicable)					
Name (Print/Type)	Edward F. Rehberg	Registration No. (Attorney/Agent)	34,703	Telephone	(269) 833-7829
Signature				Date	8-03-04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT/Docket No.: 01274.US1

**DECLARATION (37 CFR §1.63) AND POWER OF ATTORNEY**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHOD OF USING ANIMAL MODELS TO PREDICT ADVERSE DRUG REACTIONS**, Docket No. 01274.US1, the specification of which

is attached hereto.

was filed on October 20, 2003 as Application Serial No. 10/689,225.

was filed on as PCT International Application No. and was amended under PCT Article 19 on , if applicable.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, ~~as amended by any amendment referred to above.~~ *GHC*  
*June 4, 2004*

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56(a).

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below:

<u>Application Serial No.</u>	<u>Filing Date (Day/Month/Year)</u>
60/421,950	October 29, 2002

I hereby claim foreign priority benefits under 35 USC §119(a)-(d), or §365(b), of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed:

<u>Application Serial No.</u>	<u>Country</u>	<u>Filing Date (Day/Month/Year)</u>	<u>Priority Claimed (Yes/No)</u>
-----------------------------------	----------------	---	--------------------------------------

I hereby claim the benefit under 35 USC §120, of any United States application(s) or PCT International Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application: *GHC*  
*June 4, 2004*

<u>Application</u>	<u>Filing Date</u>	<u>Status (Patented, Pending, Abandoned)</u>
<u>Serial No.</u>		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint

the practitioners associated with Customer Number



25533

PATENT AND TRADEMARK OFFICE

[ ] Thomas A. Wootton (Registration No. 35,004); Lucy X. Yang (Registration No. 40,259); Edward F. Rehberg (Registration No. 34,703); John H. Engelmann (Registration No. 28,075); Austin W. Zhang (Registration No. 48,061); Stephen L. Nesbitt (Registration No. 28,981); Mary J. Hosley (Registration No. 48,324); Jonathan P. O'Brien (Registration No. 50,852); and J. Trevor Lumb (Registration No. 28,567); all registered to practice before the Patent and Trademark Office.

as my attorneys or agents with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith and request that all correspondence and telephone communications be directed to the following person at the mailing address and telephone number hereafter given:

Name : Edward F. Rehberg, Attorney

Registration No. : 34,703

Address : Pharmacia & Upjohn Company  
 Global Intellectual Property  
 301 Henrietta Street  
 Kalamazoo, Michigan 49001

Telephone No. : (269) 833-7829 or (269) 833-9500

Telefax No. : (269) 833-8897 or (269) 833-2316

Inventor's Signature Alvin H. Cantor Date June 4, 2004

Full name of sole or first inventor: Glenn H. Cantor

Residence: Kalamazoo, Michigan 49008 Hopewell Township, New Jersey 08540 Citizenship: USA

Post Office Address: 4033 East Hillandale, Kalamazoo, Michigan 49008

Post Office Address: 4055 East Hamlin Ave, Kalamazoo, Michigan 49008  
77 Elm Ridge Rd, Princeton, New Jersey 08540


Inventor's Signature

—Date

~~Full name of second joint inventor: Martin Geppert~~

Residence: ~~Glashall, Ilford, Essex, United Kingdom IG5 0BG~~ Citizenship: ~~Germany~~

Post Office Address: 33 Abbotswood Gardens, Glayhall, Ilford, Essex, United Kingdom IG5 0BG



## DECLARATION (37 CFR §1.63) AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHOD OF USING ANIMAL MODELS TO PREDICT ADVERSE DRUG REACTIONS**, Docket No. 01274.US1, the specification of which

is attached hereto.

was filed on October 20, 2003 as Application Serial No. 10/689,225.

was filed on as PCT International Application No. and was amended under PCT Article 19 on , if applicable.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56(a).

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below:

Application <u>Serial No.</u>	Filing Date <u>(Day/Month/Year)</u>
----------------------------------	--

60/421,950	October 29, 2002
------------	------------------

I hereby claim foreign priority benefits under 35 USC §119(a)-(d), or §365(b), of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed:

Application <u>Serial No.</u>	Country	Filing Date <u>(Day/Month/Year)</u>	Priority Claimed <u>(Yes/No)</u>
----------------------------------	---------	--	-------------------------------------

I hereby claim the benefit under 35 USC §120, of any United States application(s) or PCT International Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status (Patented, Pending, Abandoned)</u>
-----------------------------------	--------------------	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint

the practitioners associated with Customer Number



25533

PATENT AND TRADEMARK OFFICE

[ ] Thomas A. Wootton (Registration No. 35,004); Lucy X. Yang (Registration No. 40,259); Edward F. Rehberg (Registration No. 34,703); John H. Engelmann (Registration No. 28,075); Austin W. Zhang (Registration No. 48,061); Stephen L. Nesbitt (Registration No. 28,981); Mary J. Hosley (Registration No. 48,324); Jonathan P. O'Brien (Registration No. 50,852); and J. Trevor Lumb (Registration No. 28,567); all registered to practice before the Patent and Trademark Office.

as my attorneys or agents with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith and request that all correspondence and telephone communications be directed to the following person at the mailing address and telephone number hereafter given:

Name : Edward F. Rehberg, Attorney

Registration No. : 34,703

Address : Pharmacia & Upjohn Company  
Global Intellectual Property  
301 Henrietta Street  
Kalamazoo, Michigan 49001

Telephone No. : (269) 833-7829 or (269) 833-9500

Telefax No. : (269) 833-8897 or (269) 833-2316

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Full name of sole or first inventor: Glenn H. Cantor

Residence: Kalamazoo, Michigan 49008 Citizenship: USA

Post Office Address: 4033 East Hillandale, Kalamazoo, Michigan 49008

Inventor's Signature Martin Geppert Date 27<sup>th</sup> Feb. 2004

Full name of second joint inventor: Martin Geppert

Residence: Glayhall, Ilford, Essex, United Kingdom IG5 0BG Citizenship: Germany

Post Office Address: 33 Abbotswood Gardens, Glayhall, Ilford, Essex, United Kingdom IG5 0BG



<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>	Atty. Docket No. 01274.US1		Serial No. 10/689,225
	Applicant GH Cantor, M Geppert		
	Filing Date October 20, 2003	Group (not yet assigned)	

#### U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5,523,222	June 4, 1996	Page et. al.	435	172.3	Aug 5, 1994
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

#### FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AJ							
	AK							
	AL							
	AM							
	AN							

#### OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AO	Brayton, C., M. Justice, and C. A. Montgomery. 2001. Evaluating mutant mice: Anatomic pathology. Veterinary Pathology 38:1-19
	AP	Campbell, K.H.S., J. McWhir, W.A. Ritchie, & I. Wilmut, 1996. Sheep Cloned by Nuclear Transfer from a Cultured Cell Line, Nature 380: 64-66
	AQ	Gavaghan, C. L., E. Holmes, E. Lenz, I. D. Wilson, and J. K. Nicholson. 2000. An NMR-based metabonomic approach to investigate the biochemical consequences of genetic strain differences: application to the C57BL10J and Alpk: ApfCD mouse. FEBS Letters 484:169-174
	AR	Griebel, G., J. Simiand, R. Steinberg, M. Jung, D. Gully, P. Roger, M. Geslin, B. Scatton, J. P. Maffrand, and P. Soubrie. 2002. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. Journal of Pharmacology and Experimental Therapeutics 301:333-345

<b>LIST OF REFERENCES CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		Atty. Docket No.	Serial No.	
		01274.US1	10/689,225	
		Applicant	GH Cantor, M Geppert	
Filing Date	October 20, 2003	Group	(not yet assigned)	
	AS	Houdebine, L.M.; Transgenic Animal Generation and Use, Harwood Academic Press, 1997		
	AT	Robertson, D. G., M. D. Reily, J. C. Lindon, E. Holmes, and J. K. Nicholson. 2002. Metabonomic technology as a tool for rapid throughput in vivo toxicity screening, p. 583-626. In J. P. Vanden Heuvel, G. H. Perdew, W. B. Mattes, and W. F. Greenlee (ed.), Comprehensive Toxicology, vol. 14. Elsevier, Amsterdam		
	AU	Robertson, D. G., E. M. Urda, M. A. Breider, and R. M. Gauthier. 1998. Evaluation of hepatic toxicity of seven-day repeated-dose glutathione-depleting regimens in rats. Toxicology Methods 8:233-244		
	AV	Sundberg, J.P., and D. Boggess. 2000. Systematic approach to evaluation of mouse mutations, 1 ed. CRC Press, Boca Raton, Florida.		
	AW	Tymms, M.J., and I. Kola. 2001. Gene Knockout Protocols. Humana Press, Totawa, New Jersey.		
	AX	Ward, J. M., J.F.Mahler, R.R. Maronpot, and J.P. Sundberg. 2000. Pathology of genetically engineered mice, 1 ed. Iowa State University Press, Ames, Iowa.		
	AY	Warren, T. K., K. A. Mitchell, and B. P. Lawrence. 2000. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suppresses the humoral and cell-mediated immune responses to influenza A virus without affecting cytolytic activity in the lung. Toxicological Sciences 56:114-123		
	AZ	Wilmut, I., A.E. Schnieke, J. McWhir, A.J. Kind, & K.H.S. Campbell, 1997. Viable Offspring Derived From Fetal and Adult Mammalian Cells. Nature, 385: 810-813		
Examiner		Date Considered		